Asha Bailey, DO
Nephrology · Columbia, SCNPI 1619156957
Payments from drug & device makers
Across 556 payments — averaging $1301.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$257K
- CSL Behring$194K
- AstraZeneca$141K
- Biogen$76K
- Novartis$22K
- Astrazeneca UK Limited$20K
- plus $12K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 207 | $256,602 |
| CSL Behring | 102 | $194,301 |
| AstraZeneca(2 entities) | 40 | $141,332 |
| Biogen | 2 | $76,487 |
| Novartis | 36 | $22,437 |
| Astrazeneca UK Limited | 2 | $20,304 |
| Alnylam Pharmaceuticals Inc. | 4 | $8,798 |
| Amgen(2 entities) | 33 | $528 |
| GSK | 17 | $387 |
| Mallinckrodt Hospital Products Inc. | 9 | $352 |
| Otsuka America Pharmaceutical, Inc. | 18 | $352 |
| Vifor Pharma, Inc. | 6 | $294 |
| Calliditas Therapeutics US Inc. | 12 | $284 |
| Fresenius USA Marketing, Inc. | 13 | $218 |
| Mallinckrodt Enterprises LLC | 5 | $162 |
| Abbott | 1 | $133 |
| Aurinia Pharma U.S., Inc. | 6 | $126 |
| Travere Therapeutics, Inc. | 4 | $97 |
| Sunovion Pharmaceuticals Inc. | 10 | $93 |
| Bayer | 5 | $83 |
| Ardelyx, Inc. | 3 | $76 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $69 |
| Novo Nordisk | 3 | $68 |
| OPKO Pharmaceuticals, LLC | 4 | $65 |
| Lundbeck LLC | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Sanofi | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
How this compares
$723,891 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Columbia
- Thomas PowellColumbia$704K
- Howard LiflandColumbia$261K
- Jennifer OthersenColumbia$48K
- Renee EllisColumbia$40K
- David ShureColumbia$19K
- Niall McLaughlinColumbia$15K
- Roy MathewColumbia$10K
- Thomas WheelerColumbia$9K
- Rajeev ShenoyColumbia$8K
- Nzisa MutingaColumbia$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.